Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
34 /100
MEDIUM RISK
Score updated Aug 28, 2026

TBPH — Theravance Biopharma, Inc. Dilution Risk Tracker

Track TBPH dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track TBPH — Get alerts when the score changes →

As of August 28, 2026, Theravance Biopharma, Inc. (TBPH) has a DilutionWatch DilutionScore of 34/100, rated MEDIUM dilution risk. Theravance Biopharma, Inc. has a market capitalization of $827.94M, 51.92M shares outstanding, 174 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
40
💰Cash Runway
📊 Float Risk
60
⚠️ Warrant Exposure
40
🔄 Convertible Debt
60

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
model est. 20%
🔁 Convertible Conversion model 40%
• Significant convertible debt: 28% potential dilution
• Elevated convertible risk (60/100)
🔔 Track TBPH — Get forecast alerts →

Market Data

Market Cap$827.94M
Shares Outstanding51.92M
Float23.70M
Cash$219.77M
Debt$40.50M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 9.1% shares (2026Q1 vs prior)
174 institutional holders · 55.11M shares
#1 Madison Avenue Partners, LP 9.51M shares
#2 Weiss Asset Management LP 7.46M shares
#3 Newtyn Management, LLC 4.84M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest4.17M
Days to Cover7.5
% of Float17.6%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2022-06-30
Full SEC filing analysis available with free account

Recent News

No recent news

Factual TBPH Dilution Snapshot

Theravance Biopharma, Inc. (TBPH) has a DilutionScore of 34/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track TBPH Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking TBPH — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for TBPH
TBPH FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.